美國Gene Bridges公司中國代理：上海華雅思創(chuàng)生物科技有限公司

Company

Gene Bridges GmbH, founded 2000 as a spin-off of the European Molecular Biology Laboratories (EMBL), commercialises the patented Red/ETRecombination technology. In May 2004, Gene Bridges opened its Commercial Centre (Licensing, DNA Engineering Services, Kit development) in the Technology Park in Heidelberg.

Directors

A. Francis Stewart, Chairman, is Professor of genomics in a new research center, BIOTEC, at the Technische Universitaet Dresden. From 1991-2001 he was a Group Leader at the European Molecular Biology Laboratory (EMBL) Heidelberg, where his group specialized in advanced genetic engineering strategies using site specific and homologous recombination. Notable accomplishments were pioneering the ligand-inducible strategy of site specific recombination that is now prominent in mouse genetics; and, with Youming Zhang and Frank Buchholz, discovering Red/ET Recombination. He received his PhD from the University of N.S.W., Sydney, Australia and did post-doctoral work with Guenther Schuetz at the Deutsche Krebsforschungzentrum, Heidelberg.

Gary Stevens, Chief Executive Officer, combines more than twenty years experience in the Pharmaceutical Industry with a background in Marketing and Business Development. Prior to co-founding Gene Bridges, he worked with Hoechst and other international organisations in various European countries.

Youming Zhang, Chief Scientific Officer, is responsible for the coordination of research and development. He worked for over 5 years as a postdoctoral researcher at the University of Heidelberg and at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Youming Zhang and his colleagues discovered and developed Red/ET Recombination technologies in Francis Stewart's laboratory in EMBL, he holds a PhD degree from the University of Heidelberg, MSc degree in Molecular Biology and Biochemistry from Peking Union Medical College in China and a BSc degree in Biochemistry from the Xiamen University in China.

美國Gene Bridges品牌的產(chǎn)品在中國市場上主要是以代 理商銷售，上海華雅思創(chuàng)生物公司的核心就是在中國代理各種生物類產(chǎn)品（涉及生物醫(yī)藥、疫苗研發(fā)生產(chǎn)、生命科學(xué)研究、疾病診斷、生物工程等等）的營銷 和服務(wù)工作。

在中國地區(qū)，Gene Bridges中國代理：上海華雅思創(chuàng)生物公司起著重要的傳遞科學(xué)價值，服務(wù)科學(xué)研究。

上海華雅思創(chuàng)生物科技有限公司在中國代理 的生物類產(chǎn)品已經(jīng)成功銷往上海市、北京市、重慶市、天津市、浙江省的杭州市、寧波、溫州、江蘇省的南京市、蘇州、無錫、泰州、廣東省的廣州市、深圳 市、珠海市、江西省的南昌市、四川省的成都市、綿陽、湖南省的長沙、陜西省的西安市、楊凌、甘肅省的蘭州、寧夏的銀川、新疆的烏魯木齊、廣西的南 寧市、山東省的濟南、青島、東北三省遼寧省的沈陽市、大連市、吉林省的長春市、黑龍江省的哈爾濱市等中國絕大部分省市和自治區(qū)。

上海華雅思創(chuàng)擁有zui大的干細(xì)胞B2B資源【干細(xì)胞搜網(wǎng)】www.stemcell.so，為電子商務(wù)的*，華雅思創(chuàng)代理生物領(lǐng)域的各種品牌產(chǎn)品多達300余品牌，累計產(chǎn)品超過17000多樣，選擇好的生物干細(xì)胞實驗耗材，生物試劑類產(chǎn)品，生物儀器類產(chǎn)品，同時【干細(xì)胞搜網(wǎng)】也是zui大的干細(xì)胞資訊站，包括干細(xì)胞治療，干細(xì)胞技術(shù)動態(tài)，干細(xì)胞zui前沿的資訊，更多【干細(xì)胞資訊盡在---干細(xì)胞搜網(wǎng)】